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After decades of primarily morphological study, positional cloning of the NPHS1 gene was
the landmark event that established aberrant podocyte genetics as a pivotal cause of mal-
function of the glomerular filter.This ended any uncertainty whether genetic mutation plays
a significant role in hereditary nephrotic syndromes (NS) and confirmed podocytes as crit-
ical players in regulating glomerular protein filtration. Although subsequent sequencing
of candidate genes chosen on the basis of podocyte biology had less success, unbiased
analysis of genetically informative kindreds and syndromic disease has led to further gene
discovery. However, the 45 genes currently associated with human NS explain not more
than 20–30% of hereditary and only 10–20% of sporadic cases. It is becoming increas-
ingly clear both from genetic analysis and phenotypic data – including occasional response
to immunosuppressive agents and post-transplant disease recurrence in Mendelian dis-
ease – that monogenic inheritance of abnormalities in podocyte-specific genes disrupting
filter function is only part of the story. Recent advances in genetic screening technology
combined with increasingly robust bioinformatics are set to allow identification and charac-
terization of novel disease causing variants and more importantly, disease modifying genes.
Emerging data also support a significant but incompletely characterized immunoregulatory
component.
Keywords: podocyte nephropathy, podocytes, genetic predisposition to disease, gene mutation, nephrotic
syndrome, nephrotic genes
NEPHROTIC SYNDROME AND THE GLOMERULAR
FILTRATION BARRIER
Nephrotic syndrome (NS) is one of the commonest kidney condi-
tions to affect children and adults. It manifests as excessive leak of
protein into the urine, with interstitial edema occurring through
albumin loss, aggravated by salt and water retention. Moreover,
secondary knock-on effects on lipid metabolism, hemostasis, and
the endocrine system through loss of key binding proteins serve to
augment morbidity and mortality. NS represents a heterogeneous
group of conditions, some idiopathic, others with a clear genetic
basis. It may be highly kidney specific, associated with extra-renal
developmental malformations or occur as a complication of sys-
temic disease. The mainstay of treatment is immunosuppression,
also effective in about 8–10% of genetic cases. Non-responders
generally progress to renal failure with kidney transplantation, the
only life-saving treatment.
THE ROLE OF PODOCYTES
Despite the apparent heterogeneity, the unifying feature in NS is
malfunction of the glomerular filtration barrier (GFB). This highly
sophisticated macromolecular sieve with size and charge restrict-
ing characteristics is the primary ultra-filter of plasma by the
kidney. It allows free flow of water and small solutes but restricts
the passage of molecules >15 kDa; proteinuria occurs through
loss of these normal permselective properties. The GFB com-
prises three layers: fenestrated endothelium, glomerular basement
membrane (GBM) and podocytes, specialized terminally differen-
tiated epithelial cells connected by slit diaphragms (SD), unique
intercellular junctions interposed between interdigitating foot
processes (1). Endothelial cells and podocytes have a negatively
charged surface glycocalyx, which together with GBM sialopro-
teins and heparan sulfate gives the GFB an overall negative charge
at physiological pH. Although size is the primary determinant of
molecular filterability, recent detection of mutations in the main
component of the podocyte glycocalyx, podocalyxin, in familial
NS (2) supports additional charge selection through electrostatic
repulsion.
Although damage to any of the three layers can result in sig-
nificant proteinuria and kidney disease (3), podocytes are consid-
ered pivotal for maintaining barrier integrity. They encircle the
glomerular capillaries creating a compact interdigitating network
on the urinary side of the GFB. The connecting SDs integrate struc-
tural components of tight, adhesion, gap, and neuronal junctions
to meet the diverse functional requirements of macromolecular
filtering under high pressure while subjected to rapid changes in
mechanical shear stress (4). SDs connect with the actin cytoskele-
ton to initiate signaling pathways that regulate podocyte function,
namely plasticity of foot processes, mechanosensation, calcium
flux, endocytosis, cell polarity, and cell survival. It is perhaps not
surprising that podocyte gene mutations link to these key cellular
functions. Podocytes also react very stereotypically to injury irre-
spective of whether this is acquired or resulting from an intrinsic
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developmental defect with reorganization of the actin cytoskele-
ton, foot process effacement, molecular re-characterization of SDs,
apoptosis, and detachment from the GBM (5). These dramatic
morphological changes correlate with dysregulation of specific
markers of podocyte differentiation including WT1, PAX2, and
nephrin again signifying an underlying molecular basis. Addition-
ally, de-differentiated podocytes can attempt healing sometimes by
excessive proliferation, with the eventual outcome of repair or cell
death attributable to complex interplay of poorly defined genetic
and epigenetic mechanisms (6–8).
Clinical data support the hypothesis that the predominant cel-
lular lesion targets podocytes; GBM gene defects usually result
in insidious plasma protein leak whereas defects in podocyte/slit-
diaphragm genes cause precipitous leak and NS. Moreover, there is
evidence for a potential role for immune-regulation, particularly
in childhood. Podocytes express cytokine and chemokine recep-
tors as well as Toll Like receptors (TLRs) (9) and can respond
to immune stimuli both in vivo and in vitro. Moreover, emerg-
ing evidence indicates that podocyte injury in NS may sometimes
result from an unknown circulating factor, cytokine imbalance, or
immune complex injury, with rare genomic variants potentially
dictating susceptibility or resistance to immune triggers and the
degree of subsequent response.
ADVANCES IN MOLECULAR CHARACTERIZATION OF
PODOCYTES
Initial evidence supporting a molecular basis for NS came from
positional cloning in familial cases and experimental animal mod-
els. Inherited diseases are frequently caused by mutations in genes
with restricted expression patterns that generally do not cause
early embryonic lethality but instead manifest at the time when
gene function becomes critical for a specific tissue and subsequent
survival (10). This is certainly the case for NPHS1 and NPHS2 (11,
12), the first podocyte genes cloned in NS encoding nephrin, an
immunoglobulin superfamily member, and podocin an integral
membrane protein both exclusively expressed at the podocyte SD
supporting a key role in protein filtration. Mutations are associ-
ated with autosomal recessive NS manifesting at birth or early life
during post-natal glomerular maturation and resultant increase
in glomerular filtration.
Detection of WT1 mutations in human syndromic NS (13),
together with murine transgenic approaches using WT1, CD2AP
(14), and NEPH1 (15) underscored the contribution of develop-
mentally regulated podocyte genes. Subsequent identification of
mutations in ACTN4 (16) and INF2 (17) emphasized the central
role of the actin cytoskeleton whereas gain of function mutations
in TRCP6 linked podocyte disease to abnormalities of cellular
calcium flux and associated signaling pathways (18). Inherited
defects of mitochondrial (19) and lysosomal components (20)
have also been shown to lead to profound podocyte dysfunc-
tion, suggesting that they have high energy requirements and
turn over. This also lead to the discovery that lysosomes partici-
pate in autophagy, increasingly recognized as protecting podocytes
against injury (21, 22) Other genes such as CD2AP that partici-
pate in endocytosis and/or actin assembly have also been detected
in glomerular disease providing further important clues about
podocyte biology.
Familial and candidate gene studies have provided important
information about the molecular basis of fundamental podocyte
functions such as slit-diaphragm signaling, regulation of actin
cytoskeleton dynamics, and cell–matrix interactions. However,
until recently, only limited information about the overall genetic
landscape was available, which posed a challenge to correct inter-
pretation of genetic findings. Previously, podocytes could be
extracted with high purity, but low cell yields during isolation
hampered complete characterization of the transcriptome and
proteome. Primary cells are difficult to grow in culture, so immor-
talized podocytes provided a useful tool to study gene function
but incompletely mirrored their in vivo counterparts at molec-
ular level. However, recent development of a double fluorescent
reporter mouse model and optimized bead perfusion protocol,
combined with FACS sorting, microarray, proteomics, and unbi-
ased mathematical biology has yielded >5223 differentially regu-
lated genes within the podocyte transcriptome and >1280 trans-
lated proteins (23). These studies have revealed that the podocyte
proteome is enriched with plasma membrane, cytoskeleton, and
neuronal-type proteins. Subsequent functional analysis of tran-
scriptome and proteome data resulted in seven gene clusters:
endoplasmatic reticulum, ubiquitination, cytoskeleton, nuclear
elements, mitochondria, peroxisome and protein transport, and
cell junction. Interestingly, nuclear and translational proteins were
depleted, reflecting the post-mitotic nature of podocytes and alter-
native splicing was reduced, perhaps to ensure discreet cellular
regulation. This has also enabled more meaningful RNA sequenc-
ing, which has identified eight miRNA’s preferentially expressed
in podocytes with significantly reduction fold change of miRNA
target genes supporting miRNA-mediated mRNA degradation.
Improved description of the podocyte genome has also resulted
in more effective interpretation of data from next generation
sequencing (NGS) and to detect new variants or genes that cause
or contribute to NS. NGS allows rapid sequencing of the whole
exome or genome, and is becoming an increasingly powerful and
cost effective method of analyzing the genetic contribution to any
disorder. An unbiased approach can be taken to highlight new
genes, new pathways, and new disease mechanisms through rig-
orous statistical genetics followed by functional experiments. This
is especially relevant to NS where there is already known asso-
ciation with complex genetic determinants and this is likely to
prove important mechanistically. However, as with any rare dis-
eases, finding causal variants in NS suffers from twin problems
of moderately low sample size and disease heterogeneity. In pre-
sumed Mendelian NS, the approach is still to search for genetic
variants that segregate with disease within a family. In sporadic NS,
we hypothesize that the condition will be caused by a rare variant in
a small number of cases (limiting sample size and statistical power)
and that the variant and, indeed the gene, may vary between cases.
Added to this, although it is often assumed that there will be a
heterozygous, homozygous, or compound heterozygous change
that is causal, in common with related glomerular disorders, there
is evidence for modifier effects in NS, at the genetic (24) and
environmental level (25). This introduces the concept that NS is
more complex than the Mendelian one podocyte gene, one disease
situation as previously thought as variants are not always com-
pletely penetrant (26), synergistic activation between genes may
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occur and in non-heritable disease, an environmental trigger is
needed to cause disease. There is now clear evidence that in at
least one podocyte gene, the pathogenicity of a particular allele
depends on the trans-associated mutation (27). These concepts
are supported by increasing evidence that expected phenotype–
genotype correlations are not always adhered to and pathological
changes may develop focally (not in all glomeruli) and segmentally
(only in parts of a glomerulus), a pattern suggestive of an initial
insult precipitated by an environmental stressor, perhaps a viral
infection, that leads to localized cell injury (28).
Attempts to analyze NGS data in rare yet moderately complex
diseases such as NS initially tend to focus on three main issues,
namely how to best divide the genome for maximum signal, which
statistical test to use and how to computationally assess the func-
tion of any variants found. Unlike common complex conditions,
variants in conditions such as NS are too rare to provide mean-
ingful sample sizes for statistical testing on their own and must
be collapsed or aggregated to the level of gene, network, or other
biologically meaningful unit. That is, testing for enrichment of
variants in NS versus a control population will likely involve count-
ing the number of rare protein altering variants in each gene or
other biological unit in cases and controls and finding genes with
an excess of these rare variants, rather than searching for an enrich-
ment of any one variant as would be the case in a common complex
Genome Wide Association Study (GWAS) approach. In addition
to deciding on the biological unit by which to combine variants,
decisions also need to be made about the statistical techniques
used to combine and then analyze variants (29, 30). There are then
several databases and algorithms by which the functional delete-
riousness of potential variants can be assessed [(31): CADD; (32):
ClinVar; (33): HGMD; (34): SIFT; (35): PolyPhen]. These might
be used throughout the analysis to remove samples with known
causal variants before statistical testing, or choose likely delete-
rious variants during testing. They can also be used to examine
the likelihood that new variants might be causal prior to invest-
ing resources in replication studies or functional testing in vitro or
in vivo.Nonetheless, understanding genotype/phenotype relation-
ships without powerful systems biology tools in place has become
increasingly complicated as emerging NGS data reveal not only
considerable genetic heterogeneity but also evidence showing that
factors such as epigenetic modifications, imprinting, non-coding
RNAs, and RNA editing may play an important role in determining
phenotype (36).
PODOCYTE-SPECIFIC GENES: THE OLD AND THE NEW
Mutations in 45 genes have been associated with familial and
sporadic NS to date (Figure 1). These disrupt function either
through SD disassembly, damaging cell architecture or metabo-
lism, disturbing cell–matrix interactions, and/or impeding signal-
ing pathways. All are expressed in podocytes, but there is increasing
evidence to suggest that other systems, including immunoregula-
tory, play a role. Moreover, mutations in podocyte genes currently
only explain 20–30% of familial and 10–20% of sporadic NS.
From a clinical perspective, the renal phenotype rarely correlates
absolutely with genotype as histology overlaps, suggesting a final
common pathway to glomerular damage. Nonetheless, mode of
inheritance and age of onset can give important clues. Gene muta-
tions detected in early life are biased toward developmental genes,
podocyte/SD/GBM malformation, and autosomal recessive inher-
itance whereas in later life, mutations are more frequently autoso-
mal dominant (AD), preferentially affecting genes that participate
directly or indirectly in regulation of the actin cytoskeleton. More-
over, combined gene defects in more than one podocyte gene may
play a role in the development of NS, for example, mutations in
both NPHS1 and NPHS2 can cause a tri-allelic hit modifying phe-
notype (37), and bi-allelic trans-heterozygosity has been described
for CD2AP and NPHS2 in sporadic NS (38). Additionally,ADCK4
appears to modify CoQ10 (39) Furthermore, R229Q, a non-
neutralNPHS2 polymorphism that may predispose to NS in adults
appears pathogenic only when associated with 3′ NPHS2 muta-
tions in trans- (27), or deleterious mutation in another podocyte
gene (37). Another emerging layer of complexity is miRNAs, for
example, miR-193a downregulates the expression of WT1 in trans-
genic mice resulting in rapid and progressive NS (40). Other
genes regulate podocyte differentiation and SD function by inter-
acting synergistically on common enhancers or repressors, e.g.,
LMX1B, which combinatorially regulates NPHS2 with FoxC (41).
This underlines the likely diversity of genetic interaction within
podocytes, supporting a requirement for additional environmen-
tal factors and/or modifier genes for full phenotypic expression.
Table 1 summarizes all genes currently associated with human
NS. Broadly speaking, these can be categorized on the basis of func-
tion substantiated by the predicted effect of mutations. SD asso-
ciated and adaptor proteins normally communicate between the
SD and the podocyte cytoskeleton, forming multimeric signaling
complexes associated with lipid raft micro-domains coordinating
actin remodeling, cell survival, and endocytosis. The prototypes
are nephrin (NPHS1), and podocin (NPHS2), which interact with
proteins such as CD2AP (42) and TRPC6 to adapt between SD
and cytoskeleton through a number of cytoskeletal linkers includ-
ing F-actin and synaptopodin (43). More than 236 mutations in
NPHS1 have been described (HGMD® Professional 2014.2), and
171 mutations in NPHS2 (www.lovd.nl/NPHS2, HGMD® Profes-
sional 2014.2). CD2AP haploinsufficiency causes NS, and is asso-
ciated with trans-heterozygosity (38). Gain of function TRPC6
mutations cause AD NS mainly but not exclusively in adult life, by
increasing calcium influx and dysregulating the actin cytoskeleton
via aberrant signaling (18). Nuclear proteins regulate transcrip-
tion, podocyte differentiation and homeostasis; mutations result
in dysregulation of downstream targets often initiating cata-
strophic collapse of the entire podocyte-stabilizing system. WT1
mutations cause Denys–Drash (intersex, Wilm’s tumor, NS) and
Frasier syndromes (intersex, NS, gonadoblastoma) and AD adult
onset NS (44). LMX1B, a homeobox transcription factor, regulates
SDs and is essential for the maintenance of the actin cytoskeleton.
Haploinsufficiency causes Nail–Patella syndrome, a rare AD NS
that can occur as just kidney specific disease (45). The most recent
gene to be cloned is WDR73, its exact function in the podocyte
is as yet unknown but mutations result in Galloway–Mowat syn-
drome, a rare association between microcephaly, diaphragmatic
hernia, and SRNS (46). Proteins regulating the actin cytoskeleton
are also targeted. ACTN4 (α-actinin-4) causes AD adult onset
NS with incomplete penetrance. Here, mutant proteins show
stronger affinity for F-actin and impair cytoskeletal function.
Another actin regulating gene, INF2 belongs to the formin family
and normally homodimerizes to inhibit actin depolymerization.
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FIGURE 1 | Schematic view of podocyte genes associated with steroid
resistant nephrotic syndrome (with reference toTable 1). Podocyte cell
with foot processes, slit diaphragm, the glomerular basement membrane
(GBM), and fenestrated endothelium are shown. N, podocyte nucleus; ER,
endoplasmic reticulum; M, mitochondrion. Slit diaphragm associated and
adaptor proteins: nephrin (NPHS1), podocin (NPHS2), CD2-associated protein
(CD2AP ), PLCε1 (PLCE1), transient receptor potential channel 6 (TRPC6 ), and
protein tyrosine phosphatase receptor type O (PTPRO). Nuclear proteins and
transcription factors: Wilm’s tumor protein (WT1), SWI/SNF-related
matrix-associated actin-dependent regulator of chromatin subfamily A-like
protein 1 (SMARCAL1), LIM Homeobox Transcription Factor 1β (LMX1B),
nuclear RNA export factor 5 (NXF5 ), paired box protein (PAX2) and
transcription factor E2F3 (E2F3), lamin A/C (LMNA), zinc metallopeptidase
STE24 (ZMPSTE24). Actin cytoskeleton and signalling: podocalyxin (PODXL),
inverted formin 2 (INF2), α-actinin-4 (ACTN4), synaptopodin (SYNPO), myosin
1E (MYO1E ), Rho-GDP-dissociation inhibitor 1 (ARHGDIA), and
Rho-GTPase-activating protein 24 (ARHGAP24), and actin-binding protein
anillin (ANLN ), cubilin (CUBN ), tetratricopeptide repeat protein 21B (IFT139,
TTC21B); epithelial membrane protein 2 (EMP2). Mitochondria-associated
proteins: parahydroxybenzoate-polyprenyl transferase (COQ2), ubiquinone
biosynthesis monooxygenase (COQ6 ), decaprenyl-diphosphate synthase
subunit 2 (PDSS2), AarF domain-containing kinase 4 (ADCK4), and
mitochondrially encoded tRNA leucine 1 (MTTL1). Metabolic and lysosomal
proteins: chitobiosyldiphosphodolichol β-mannosyltransferase (ALG1),
phosphomannomutase 2 (PMM2), and scavenger receptor class B, member
2 (SCARB2). GBM associated proteins: collagen 4 – COL4A3, 4, 5 ;
integrin-α3 (ITGA3), integrin-β4 (ITGB4), laminin-β2 (LAMB2); CD151 antigen
(CD151).
Mutations are detected in a significant proportion of familial but
not sporadic NS. Mutations in PLCe1 (phospholipase C epsilon)
mostly cause early-onset NS by dysregulating the cytoskeleton
and signaling, and may be variably penetrant with some mis-
sense mutations resulting in later onset disease responding to
immunosuppression (47).PLCe1mutations may also co-exist with
trans-heterozygote mutations in other podocyte genes. PTPRO
encodes a protein tyrosine phosphatase receptor located on the
apical side of podocyte foot processes that controls the glomeru-
lar pressure/filtration rate (48). Only two splice-site mutations
have been detected in PTPRO and cases partially responded to
immunosuppression (49). Recently, mutations in ANLN (anillin),
another F-Actin binding protein, were detected in familial NS (50),
and other mutation screens of inherited disease have identified
ARHGDIA (51) andARHGAP24 (52), underpinning a key role for
RHO GTPases and Rho–Rac signaling in regulating the podocyte
cytoskeleton. MYO1E (53) and MYH9 (24), mutated in autoso-
mal recessive NS regulate actin cytoskeletal function and cell shape.
APOL1 mutations also result in increased NS in African Ameri-
cans but the mechanism remains unclear (54). Mutations affecting
protein expressed in the GBM may also disrupt GFB functions
sufficiently to cause NS. LAMB2 mutations, encoding laminin β2,
cause Pierson’s syndrome characterized by early-onset NS with or
without microcoria, depending on the severity of the mutation
(55). ITGA3 and ITGB4 encode integrins thought to be mainly
passive GBM stabilizers, with mutations causing hyperglycosyla-
tion that prevents formation of functional integrins manifesting as
NS and skin defects (56). COL4A3, A4, and A5 are key GBM pro-
teins that cause Alport’s syndrome; recent data suggest caution in
interpreting COL4A variants detected in apparent familial NS (57).
Mitochondrial and other rare metabolic syndromes also present
with NS, by disrupting podocyte metabolism.
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Table 1 | Genes directly associated nephrotic syndrome.
Gene Inheritance Disease association and onset
SDASSOCIATEDANDADAPTOR PROTEINS
NPHS1 AR CNS/NS
NPHS2 AR CNS, NS – childhood and adult onset
CD2AP ? Early-onset NS, HIV nephropathy
PLCe1 AR Early-onset NS
TRPC6 AD Adult onset NS
PTPRO AR Childhood-onset NS
NUCLEAR PROTEINS
WT1 Sporadic; AD Adult onset NS, Denys–Drash and Frasier Syndromes
LMX1B AR Nail–Patella Syndrome/NS only
SMARCAL1 AR Schimke immuno-osseous dysplasia
E2F3 Chromosomal deletion Early-onset NS and mental retardation
NXF5 X-linked recessive NS with co-segregating heart block disorder
PAX2 AD Adult onset NS
WDR73 AR Galloway–Mowat Syndrome
ACTIN CYTOSKELETONAND SIGNALING
ACTN4 AD Adult onset NS
MYH9 Risk allele Adult onset NS
INF2 AD Familial/sporadic NS; Charcot-Marie-Tooth
SYNPO ? Adult onset NS
APOL1 Complex; AR Adult onset NS
MYO1E AR Early or adult onset NS
ARHGAP24 AD Adult onset NS
ARHGDIA AR CNS
ANLN AD Adult onset NS
EMP2 AR Childhood-onset NS
CUBN AR Intermittent nephrotic range proteinuria and epilepsy
GPC5 Risk allele Adult onset NS
PODXL AD Early or adult onset NS
TTC21B AR NS with tubulointerstitial involvement
CLTA4 Risk allele Sporadic NS
MITOCHONDRIAL
MTTL1 ? MELAS syndrome; NS±deafness and diabetes
tRNAIle ? Deafness, NS, epilepsy, and dilated cardiomyopathy
tRNAAsn ? Multiorgan failure and NS
tRNATyr ? Mitochondrial cytopathy and NS
COQ2 AR Mitochondrial disease/isolated nephropathy
COQ6 AR NS with sensorineural deafness
ZMPSTE24 AR Mandibuloacral dysplasia with NS
PDSS2 AR Leigh syndrome
ADCK4 AR NS
CYP11B2 Risk allele C-344T SNP risk factor for IgA nephropathy, NS, proliferative glomerulopathy
GBM
LAMB2 AR Pierson syndrome: CNS with ocular abnormalities; isolated early-onset NS
ITGB4 AR NEP syndrome-NS, epidermolysis bullosa, and pulmonary disease
ITGA3 AR Epidermolysis bullosa and pyloric atresia+NS
(Continued)
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Table 1 | Continued
Gene Inheritance Disease association and onset
LMNA AD Familial partial lipodystrophy+NS
COL4A3 AR Alport’s disease
COL4A4 AR Alport’s disease
COL4A5 X-linked Alport’s disease
CD151 AR NS, pretibial bullous skin lesions, neurosensory deafness, bilateral lacrimal duct stenosis,
nail dystrophy, thalassemia minor
OTHER – METABOLIC OR LYSOSOMAL
PMM2 AR Congenital disorder of glycosylation
ALG1 AR Congenital disorder of glycosylation
SCARB2 (lysosome) AR Action myoclonus renal failure syndrome±hearing loss
AR, autosomal recessive; AD, autosomal dominant; CNS, congenital nephrotic syndrome; NS, nephrotic syndrome; ?, inheritance neither clearly autosomal dominant
or recessive, possibly complex.
Initial identification of monogenic defects correlating with
morphological findings in podocytes in health and disease
provided important mechanistic insights. However, this is now
too simplistic, a model; podocyte genetic mechanisms are becom-
ing increasingly complex, perhaps not surprising considering their
super-specialist role within the GFB. Multiple levels of control
involving modifier genes and di-genic and multi-genic inheritance
are undoubtedly necessary to deal with epigenetic events and envi-
ronmental effects (58). It is also likely that some gene variants are
not directly causative, but rather modifiers of phenotype that may
even arise from primary immune injury or presence of a circu-
lating permeability factor. The advent of NGS and increasingly
sophisticated bioinformatics approaches pave the way for exciting
exploration of these alternative mechanisms, which undoubtedly
play a key role in podocyte pathobiology.
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